Medexus Pharmaceuticals Inc
MDP
Company Profile
Business description
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
Contact
10 King Street East
Suite 600
TorontoONM5C 1C3
CANT: +1 514 762-2626
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
91
Stocks News & Analysis
stocks
Strong finish to the year for overvalued ASX share
A great fiscal 2025 but investors are ahead of themselves.
stocks
Our three most overvalued ASX shares
These three companies are trading at a significant premium to our fair value.
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,080.70 | 39.80 | -0.44% |
| CAC 40 | 7,734.84 | 60.06 | 0.78% |
| DAX 40 | 23,807.13 | 210.15 | 0.89% |
| Dow JONES (US) | 45,514.95 | 114.09 | 0.25% |
| FTSE 100 | 9,221.44 | 13.23 | 0.14% |
| HKSE | 25,808.70 | 174.79 | 0.68% |
| NASDAQ | 21,798.70 | 98.31 | 0.45% |
| Nikkei 225 | 43,459.29 | 184.52 | -0.42% |
| NZX 50 Index | 13,253.73 | 27.41 | -0.21% |
| S&P 500 | 6,495.15 | 13.65 | 0.21% |
| S&P/ASX 200 | 8,803.50 | 37.40 | -0.42% |
| SSE Composite Index | 3,809.43 | 17.41 | -0.45% |